JP2019508370A5 - - Google Patents

Download PDF

Info

Publication number
JP2019508370A5
JP2019508370A5 JP2018532465A JP2018532465A JP2019508370A5 JP 2019508370 A5 JP2019508370 A5 JP 2019508370A5 JP 2018532465 A JP2018532465 A JP 2018532465A JP 2018532465 A JP2018532465 A JP 2018532465A JP 2019508370 A5 JP2019508370 A5 JP 2019508370A5
Authority
JP
Japan
Prior art keywords
patient
ccl20
level
disease
pharmaceutical composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2018532465A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019508370A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2016/067120 external-priority patent/WO2017112536A1/en
Publication of JP2019508370A publication Critical patent/JP2019508370A/ja
Publication of JP2019508370A5 publication Critical patent/JP2019508370A5/ja
Priority to JP2021172872A priority Critical patent/JP2022031643A/ja
Pending legal-status Critical Current

Links

JP2018532465A 2015-12-22 2016-12-16 Ｉｌ２３アンタゴニストに対する臨床応答の予測因子としてのｃｃｌ２０ Pending JP2019508370A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2021172872A JP2022031643A (ja) 2015-12-22 2021-10-22 Ｉｌ２３アンタゴニストに対する臨床応答の予測因子としてのｃｃｌ２０

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562271156P 2015-12-22 2015-12-22
US62/271,156 2015-12-22
PCT/US2016/067120 WO2017112536A1 (en) 2015-12-22 2016-12-16 Ccl20 as a predictor of clinical response to il23-antagonists

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2021172872A Division JP2022031643A (ja) 2015-12-22 2021-10-22 Ｉｌ２３アンタゴニストに対する臨床応答の予測因子としてのｃｃｌ２０

Publications (2)

Publication Number Publication Date
JP2019508370A JP2019508370A (ja) 2019-03-28
JP2019508370A5 true JP2019508370A5 (https=) 2020-06-25

Family

ID=59091179

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2018532465A Pending JP2019508370A (ja) 2015-12-22 2016-12-16 Ｉｌ２３アンタゴニストに対する臨床応答の予測因子としてのｃｃｌ２０
JP2021172872A Pending JP2022031643A (ja) 2015-12-22 2021-10-22 Ｉｌ２３アンタゴニストに対する臨床応答の予測因子としてのｃｃｌ２０

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2021172872A Pending JP2022031643A (ja) 2015-12-22 2021-10-22 Ｉｌ２３アンタゴニストに対する臨床応答の予測因子としてのｃｃｌ２０

Country Status (12)

Country Link
US (2) US11220541B2 (https=)
EP (1) EP3393515A4 (https=)
JP (2) JP2019508370A (https=)
KR (1) KR20180096633A (https=)
CN (1) CN108472367A (https=)
AU (1) AU2016379157A1 (https=)
BR (1) BR112018012626A2 (https=)
CA (1) CA3007098A1 (https=)
IL (1) IL259704A (https=)
MX (1) MX2018007589A (https=)
RU (1) RU2018124603A (https=)
WO (1) WO2017112536A1 (https=)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JO3244B1 (ar) 2009-10-26 2018-03-08 Amgen Inc بروتينات ربط مستضادات il – 23 البشرية
CN108290058B (zh) 2015-09-17 2023-05-16 美国安进公司 使用il23途径生物标志物预测il23拮抗剂的临床应答
IL326284A (en) * 2018-09-24 2026-04-01 Janssen Biotech Inc A safe and effective method for treating ulcerative colitis with an anti-IL12/IL23 antibody
CN108957014A (zh) * 2018-09-27 2018-12-07 郑州大学第附属医院 结直肠癌血清标志物、表达评估方法、试剂盒及应用
EP3946592A4 (en) * 2019-03-26 2023-01-04 Astrazeneca Collaboration Ventures, LLC PATIENT POPULATIONS LIKELY TO BENEFIT FROM IL23 ANTAGONIST THERAPY
CN116782827A (zh) 2020-11-30 2023-09-19 明德拉公司 微针装置和方法以及皮肤病状测定
CN113092652B (zh) * 2021-03-19 2022-09-30 浙江工商大学 一种用于评估个体过敏程度的试剂盒
CN114113630B (zh) * 2021-11-24 2023-07-28 中南大学湘雅医院 Serpinb3/b4作为靶点在玫瑰痤疮等炎症性皮肤病治疗药物中的应用

Family Cites Families (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8318754D0 (en) 1983-07-11 1983-08-10 Fagerhol M K F Human proteins anti-sera test kits
US5892019A (en) 1987-07-15 1999-04-06 The United States Of America, As Represented By The Department Of Health And Human Services Production of a single-gene-encoded immunoglobulin
US5455160A (en) 1993-05-27 1995-10-03 Fagerhol; Magne K. Diagnostic test and kit for disease or disorders in the digestive system
AU4790597A (en) 1996-11-01 1998-05-29 Nycomed Pharma As Process for the extraction of proteins
US6171586B1 (en) 1997-06-13 2001-01-09 Genentech, Inc. Antibody formulation
ZA986596B (en) 1997-07-25 1999-02-08 Schering Corp Mammalian cytokine related reagents
WO2005086835A2 (en) 2004-03-05 2005-09-22 Archemix Corp. Aptamers to the human il-12 cytokine family and their use as autoimmune disease therapeutics
CA2565701A1 (en) 2004-05-06 2005-11-17 Jonathan M. Barasch Ngal for reduction and amelioration of ischemic and nephrotoxic injuries
KR100681763B1 (ko) 2005-02-28 2007-02-15 재단법인 목암생명공학연구소 인간 리포칼린 2를 유효성분으로 포함하는 암 전이 억제용약학적 조성물, 이를 이용한 암 전이 억제 방법
SI2452694T1 (sl) 2005-06-30 2019-05-31 Janssen Biotech, Inc. Protitelesa proti-IL-23, sestavki in postopki uporabe
DE602006015830D1 (de) 2005-08-25 2010-09-09 Lilly Co Eli Anti-il-23-antikörper
PT1931710T (pt) 2005-08-31 2017-03-28 Merck Sharp & Dohme Anticorpos anti-il-23 manipulados
BRPI0619118A2 (pt) 2005-12-02 2011-09-13 Genentech Inc composições e métodos para o tratamento de doenças e desordens associadas com a sinalização de citocina
HUE034269T2 (en) 2005-12-29 2018-02-28 Janssen Biotech Inc Human anti-IL-23 antibodies, preparations, methods and applications
WO2007098065A2 (en) 2006-02-17 2007-08-30 The United States Of America As Represented By The Department Of Veterans Affairs Human sodium channel isoforms
US7790862B2 (en) 2006-06-13 2010-09-07 Zymogenetics, Inc. IL-17 and IL-23 antagonists and methods of using the same
ES2708988T3 (es) 2007-02-23 2019-04-12 Merck Sharp & Dohme Anticuerpos anti-IL-23p19 obtenidos por ingeniería genética
JP2010518858A (ja) 2007-02-23 2010-06-03 シェーリング コーポレイション 操作された抗−ｉｌ−２３ｐ１９抗体
AR068723A1 (es) 2007-10-05 2009-12-02 Glaxo Group Ltd Proteina que se une a antigenos que se une a il-23 humana y sus usos
WO2009082624A2 (en) 2007-12-10 2009-07-02 Zymogenetics, Inc. Antagonists of il-17a, il-17f, and il-23 and methods of using the same
US7833720B2 (en) 2008-03-14 2010-11-16 Exagen Diagnostics, Inc. Biomarkers for inflammatory bowel disease and irritable bowel syndrome
EP2331078B1 (en) 2008-08-27 2012-09-19 Merck Sharp & Dohme Corp. Lyophilized formulations of engineered anti-il-23p19 antibodies
US20100221752A2 (en) 2008-10-06 2010-09-02 Somalogic, Inc. Ovarian Cancer Biomarkers and Uses Thereof
US20100093552A1 (en) 2008-10-09 2010-04-15 Asit Panja Use and identification of biomarkers for gastrointestinal diseases
JP2012507723A (ja) * 2008-11-03 2012-03-29 シェーリング コーポレイション 炎症性腸疾患生物マーカーおよび関連治療方法
US20120128689A1 (en) 2009-04-01 2012-05-24 Glaxo Group Limited Anti-il-23 immunoglobulins
WO2010129964A1 (en) 2009-05-08 2010-11-11 The Board Of Trustees Of The University Of Illinois Drug targets for prevention of arrhythmia in heart disease
US20120264917A1 (en) 2009-05-27 2012-10-18 Ablynx N.V. Biparatopic protein constructs directed against il-23
EP3309556B1 (en) 2009-06-25 2020-04-08 Prometheus Biosciences, Inc. Methods for diagnosing irritable bowel syndrome
JO3244B1 (ar) 2009-10-26 2018-03-08 Amgen Inc بروتينات ربط مستضادات il – 23 البشرية
CA2781654A1 (en) 2009-11-25 2011-06-03 Hua Gong Novel genomic biomarkers for irritable bowel syndrome diagnosis
PH12012501364A1 (en) 2010-01-15 2012-10-22 Amgen K A Inc Antibody formulation and therapeutic regimens
WO2012009760A1 (en) 2010-07-20 2012-01-26 Cephalon Australia Pty Ltd Anti-il-23 heterodimer specific antibodies
US8541180B1 (en) 2010-10-11 2013-09-24 Genova Diagnostics, Inc. Compositions and methods for assessing gastrointestinal health
MX2019000046A (es) 2010-11-04 2023-10-05 Boehringer Ingelheim Int Anticuerpos anti-il-23.
BR112013017445A2 (pt) 2011-01-06 2016-08-23 Univ Illinois métodos de determinar a necessidade de um indivíduo para um desfibrilador cardíaco implantado (icd) e para uma terrapia antiarrítmica, de determinar o risco de um indivíduo para uma morte cardiáca súbita, para arritmias e para insuficiência cardíaca, de reduzir risco de morte cardíaca súbita em um indivíduo, kit, sistema, meio de armazenamento legível por computador, e, método implementado por um processador em um computador
WO2012158831A1 (en) 2011-05-16 2012-11-22 Prometheus Laboratories Inc. Performance of a biomarker panel for irritable bowel syndrome
NO336551B1 (no) 2011-06-21 2015-09-28 Magne Fagerhol Forbedret ELISA for kalprotektin i fekalprøve eller gastrointestinaltraktsprøve
NO20110895A1 (no) 2011-06-21 2012-12-24 Magne Fagerhol Kompetitive S100A9 immunoanalyser
WO2013132338A2 (en) 2012-03-06 2013-09-12 Calpro As Competitive immunoassay for calprotectin
WO2013132347A2 (en) 2012-03-06 2013-09-12 Calpro As Improved elisa immunoassay for calprotectin
WO2013152114A1 (en) 2012-04-03 2013-10-10 The Regents Of The University Of Michigan Biomarker associated with irritable bowel syndrome and crohn's disease

Similar Documents

Publication Publication Date Title
JP2018535394A5 (https=)
JP2019508370A5 (https=)
RU2018113694A (ru) Прогноз клинического ответа на антагонисты ил-23 с использованием биомаркеров сигнального пути ил-23
RU2018124603A (ru) Ccl20 как прогностический фактор клинического ответа на антагонисты ил-23
Yamamoto et al. Value of serum IgG4 in the diagnosis of IgG4-related disease and in differentiation from rheumatic diseases and other diseases
Ha et al. Usefulness of serum leucine-rich alpha-2 glycoprotein as a disease activity biomarker in patients with rheumatoid arthritis
WO2011100637A1 (en) Markers for determination of patient responsiveness
Majeed et al. Serum profiles of pro-inflammatory and anti-inflammatory cytokines in non-hospitalized patients with mild/moderate COVID-19 infection.
BR112016005745B1 (pt) Biomarcadores para tuberculose
EP3077818B1 (en) Methods for predicting post-operative recurrence of crohn's disease
Chen et al. Presence of hepatitis B virus in synovium and its clinical significance in rheumatoid arthritis
TWI655433B (zh) 川崎氏症之診斷與治療
Pisani et al. Proteomic insights on the metabolism in inflammatory bowel disease
Liao et al. Association of C-type lectin 18 levels with extrahepatic manifestations in chronic HCV infection
Fouladseresht et al. Anti-varicella zoster virus IgG and hsCRP levels correlate with progression of coronary artery atherosclerosis
JP2025533470A (ja) Ｈｂｖの診断、予後判定及び治療の方法並びに製品
Gong et al. Serum progranulin levels are elevated in patients with chronic hepatitis B virus infection, reflecting viral load
Lian et al. Serum levels of preS antigen (HBpreSAg) in chronic hepatitis B virus infected patients
Ra et al. Kinetics of Serological Response in Patients with Severe Fever with Thrombocytopenia Syndrome. Viruses 2021, 13, 6
WO2015166461A1 (en) Methods of selecting treatment regimen using tnf alpha and anti-tnf alpha drug levels
Kelvin Ethan B. Jansen, Ali Toloue Ostadgavahi 3, Benjamin Hewins 3, Rachelle Buchanan, Brittany M. Thivierge, Gustavo Sganzerla Martinez 3, Una Goncin 4, Magen E. Francis, Cynthia L. Swan, Erin Scruten, Jack Bell, Joseph Darbellay, Antonio Facciuolo, Darryl Falzarano, Volker Gerdts, Mark E. Fenton 6, Peter Hedlin 4, David J. Kelvin 3 &
TW201445140A (zh) 腫瘤壞死因子受體相關因子７作爲紅斑性狼瘡的生物標記物之用途、偵測人體患有紅斑性狼瘡的方法以及偵測人體患有紅斑性狼瘡的套組
Hussein et al. Clinical Relevance Of Anti-Cyclic Citrullinated Peptide Antibodies In Rheumatoid Arthritis
Halicioglu et al. PVI-26 Hepatitis A seroprevalence in pediatric patients in west part of Turkey
Zer et al. PVI-25 The effect of autoantibodies to test results in patients with low-titre anti-HCV positivity